Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Bride Cancels Engagement Photos To Share Special Dance With Terminal Dad. April 19, 2019 Interactive App Improves Colorectal Cancer Screening Rates April 9, 2018 FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma February 7, 2022 How to Strengthen Your Immune System: Part 1 September 17, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... 9 Ways to Use Social Media for Support Throughout Your Cancer... Researchers Find a Way to Prevent Cancer Cells from Taking in... TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness...
